How to Vet a Compounding Pharmacy: A 10-Point Checklist
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency.
You found a telehealth program that prescribes compounded semaglutide or tirzepatide. The price looks reasonable and the website looks professional. But the medication itself will come from a pharmacy you have probably never heard of, and that pharmacy matters more to quality than anything on the program’s homepage.
You can check it yourself. Most of the records you need are public and free, and the rest you can ask for. This page is the checklist: ten things to verify, how to verify each one, and where the information comes from.
Transformation Health is an independent guide. It does not vet, partner with, or work with any pharmacy, and it does not rank or recommend pharmacies. Everything below is a check you run on whichever pharmacy your provider or program uses.
Start with one question: which pharmacy?
At most telehealth programs, you do not pick the pharmacy. The program sends the prescription to a pharmacy it works with. So the first step is simply to ask: “What is the name of the pharmacy that will prepare my medication, what state is it in, and what is its license number?”
A program should answer that plainly. “We work with a network of pharmacies” is not an answer. Once you have a name, you can run every check below.
The checklist
1. US-based and licensed in your state
What to check: The pharmacy has a physical address and phone number in the United States and an active license from a state board of pharmacy, including the board in the state where you live.
How to check: Use the FDA's BeSafeRx page "Locate a State-Licensed Online Pharmacy" to open your state's license database and search for the pharmacy. If it is not listed, the FDA says not to use it. A pharmacy that ships across state lines may need a separate license from the state it ships to, so check your state's board, not only its home state's.
Source: FDA BeSafeRx[2][3]; ACHC[9]
2. Requires a valid prescription
What to check: The pharmacy fills compounded GLP-1 medication only on a prescription from a licensed provider who has reviewed your health history.
How to check: If anyone offers semaglutide or tirzepatide without a prescription, stop there. The FDA lists always requiring a prescription as a sign of a safe online pharmacy, and federal law ties 503A compounding to a valid prescription for an identified patient.
Source: FDA BeSafeRx[2]; 21 U.S.C. 353a[7]
3. 503A pharmacy or 503B outsourcing facility
What to check: Which type it is. A 503A pharmacy compounds for individual patients and is overseen mainly by its state board. A 503B outsourcing facility registers with the FDA, is inspected on a risk-based schedule, and must meet current good manufacturing practice (CGMP) requirements.
How to check: Ask. If the answer is 503B, find the facility on the FDA's Registered Outsourcing Facilities list and note the last inspection date, whether a Form FDA 483 was issued, whether a recall was conducted, and any action taken. Neither type makes a product FDA-approved. For more, see 503A vs 503B pharmacies.
Source: FDA[4][5]
4. Inspection and enforcement history
What to check: FDA warning letters, Form 483 observations, and state board disciplinary actions against the pharmacy.
How to check: Search the pharmacy's name in the FDA's warning letter database. Then check the state board of pharmacy in the state where the pharmacy is located; the FDA's outsourcing facility list does not include state actions. A Form 483 is not a final agency determination, but recent or repeated problems are worth asking about.
Source: FDA[5][6]
5. Test results for your lot
What to check: A certificate of analysis (COA) for the lot you receive. Ask who ran the test (an independent lab or the pharmacy's own lab), what was tested (potency, and for an injectable, sterility and endotoxins), and when.
How to check: Match the lot number on the COA to the lot number on your vial. Traditional 503A pharmacies are not subject to CGMP requirements, so testing practices vary. A pharmacy that tests should be able to tell you what it tests for. If it cannot, ask why.
Source: FDA[4]
6. Ingredient form and source
What to check: What form of the active ingredient the pharmacy uses (for semaglutide, not a salt form) and where that ingredient was made.
How to check: Ask what form of semaglutide or tirzepatide the pharmacy uses. The FDA says salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients, and it is not aware of any lawful basis for using them in compounding. Ask where the active ingredient comes from. Under import alert 66-80, the FDA can detain GLP-1 bulk ingredients at the border unless the manufacturer is on the alert's "Green List."
Source: FDA[1][10]
7. The label
What to check: The label names the pharmacy you looked up, its address, a lot number, and a beyond-use or expiration date. If it came from a 503B outsourcing facility, federal law requires the statement "This is a compounded drug" (or a comparable statement), the facility's name, address, and phone number, the lot number, and the expiration date.
How to check: Compare the label with what you were told. The FDA lists spelling errors on the label, incorrect pharmacy addresses, and pharmacy names that might be fraudulent as red flags.
Source: FDA[1]; 21 U.S.C. 353b(a)(10)[8]
8. Shipping and storage
What to check: Injectable GLP-1 medication arrives cold, in insulated packaging with enough ice packs.
How to check: Check the package as soon as it arrives. The FDA has received complaints about compounded GLP-1 drugs arriving warm and recommends not using any injectable GLP-1 drug that arrives warm or without enough refrigeration. Contact the pharmacy and your prescriber, and you can report a quality problem to the FDA's MedWatch program.
Source: FDA[1][11]
9. Accreditation
What to check: Whether the pharmacy holds PCAB accreditation, which is now offered through the Accreditation Commission for Health Care (ACHC).
How to check: Ask, then confirm with ACHC directly rather than relying on a logo on a website. Accreditation is a private credential a pharmacy chooses to seek. It does not replace a state license, and a pharmacy without it can still be properly licensed.
Source: ACHC[9]
10. Reviews, ratings, and complaints
What to check: What other customers report about shipping, billing, and customer service. Treat this as one signal, not proof of quality.
How to check: Read reviews with care. Since October 21, 2024, an FTC rule has barred fake reviews, buying reviews that express a particular opinion, and undisclosed reviews by company insiders, but such reviews still appear. Reviews cannot tell you whether a vial is sterile or contains the labeled strength, and many reviews describe the telehealth program, not the pharmacy. For complaints with teeth, check the state board of pharmacy and your state attorney general's consumer protection office.
Source: FTC, 16 CFR Part 465[12]
Passing every item does not make a compounded medication FDA-approved. It tells you the pharmacy is licensed, accountable to a regulator, and willing to show its work. For a longer walkthrough of each credential, see how to choose a safe compounding pharmacy.
Red flags: when to stop
The FDA publishes warning signs for online pharmacies and for telehealth companies selling GLP-1 drugs. If you see any of these, do not order[1][2]:
- It will sell without a prescription. GLP-1 medications are prescription-only, and a licensed provider decides whether one is appropriate.
- “For research purposes” or “not for human consumption.” The FDA has warned companies selling semaglutide, tirzepatide, and other GLP-1 ingredients with these labels and urges consumers not to buy them.
- Claims of sameness. The FDA lists a company claiming its compounded drug matches an FDA-approved drug as a telehealth red flag.
- Prices that seem too good to be true. The FDA lists deep discounts as a warning sign for both online pharmacies and telehealth companies.
- No US physical address or phone number, or no state board of pharmacy license you can find.
- The program will not name the pharmacy, or the pharmacy on your label does not match the one you were told.
- Medicine that looks different from what you were shown, or arrives in broken or damaged packaging or without instructions.
For dated FDA recalls and alerts involving compounded GLP-1 medications, see GLP-1 recalls and safety alerts.
Questions to ask your provider or program
Bring these to the program before you pay. A legitimate program should be able to answer every one.
- Which pharmacy fills my prescription? What state is it in, and what is its license number?
- Is it a 503A pharmacy or a 503B outsourcing facility?
- Is the pharmacy licensed in my state?
- Can I see the certificate of analysis for my lot? Who ran the tests, and what was tested?
- What form of semaglutide or tirzepatide does the pharmacy use, and where does the active ingredient come from?
- How is the medication shipped, and what should I do if it arrives warm?
- If the pharmacy changes, will you tell me before my next shipment?
For the program side of the decision (prescriber credentials, total cost at each dose, cancellation terms), see how to choose a compounded GLP-1 provider.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedImportant disclosures
This content is for general education and is not medical advice. Talk with a licensed provider about your situation. A licensed provider decides whether a prescription is appropriate.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before they are marketed[1][4]. Compounded semaglutide and tirzepatide are not the same as brand-name products, and they may differ in formulation, purity, and potency. FDA registration of a 503B outsourcing facility is not FDA approval of the products it makes.
Regulatory status is subject to change. On December 19, 2024, the FDA reissued its determination that the tirzepatide injection shortage was resolved. On February 21, 2025, it determined that the semaglutide injection shortage was resolved. The FDA says tirzepatide and semaglutide do not currently appear on the 503B bulks list or on its drug shortage list; that FDA page is current as of April 1, 2026[13]. Availability of compounded GLP-1 medications depends on federal and state law and FDA action, and cannot be guaranteed.
This checklist does not endorse any pharmacy, provider, or product.
Citations
[1] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: telehealth red flags, including “same as” claims, deep discounts, packaging problems, no screening and prescription, label spelling errors, incorrect pharmacy addresses, and possibly fraudulent pharmacy names; fraudulent compounded labels; semaglutide salt forms; import alert 66-80; warm shipments; products labeled for research or not for human consumption; compounded drugs not reviewed by FDA.)
[2] U.S. Food and Drug Administration. “BeSafeRx: Considering an Online Pharmacy?” Content current as of 09/21/2020. https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy (Accessed 2026-10-16. Supports: safe signs, including always requiring a prescription, a US physical address and phone number, a licensed pharmacist, and a state board license; warning signs, including no prescription, not licensed in the US and by your state board, damaged packaging, and deep discounts.)
[3] U.S. Food and Drug Administration. “BeSafeRx: Locate a State-Licensed Online Pharmacy.” Content current as of 11/13/2024. https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/locate-state-licensed-online-pharmacy (Accessed 2026-10-16. Supports: links to each state’s board of pharmacy license database; if the pharmacy is not listed, do not use it.)
[4] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs not FDA-approved; state board oversight of 503A pharmacies; FDA oversight and risk-based inspection of outsourcing facilities; CGMP applies to outsourcing facilities and not to 503A pharmacies.)
[5] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” Content current as of 10/13/2026; table updated as of 9/30/2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16. Supports: list of registered 503B facilities with last inspection, Form 483, recall, and action columns; a Form 483 is not a final agency determination; table excludes state board actions.)
[6] U.S. Food and Drug Administration. “Warning Letters.” Content current as of 10/13/2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters (Accessed 2026-10-16. Supports: FDA’s searchable public warning letter database.)
[7] Federal Food, Drug, and Cosmetic Act section 503A, 21 U.S.C. 353a. https://www.law.cornell.edu/uscode/text/21/353a (Accessed 2026-10-16. Supports: 503A compounding for an identified individual patient based on a valid prescription order, by a licensed pharmacist in a state-licensed pharmacy.)
[8] Federal Food, Drug, and Cosmetic Act section 503B, 21 U.S.C. 353b. https://www.law.cornell.edu/uscode/text/21/353b (Accessed 2026-10-16. Supports: 503B(a)(10) label requirements, including “This is a compounded drug” or a comparable statement, the facility’s name, address, and phone number, the lot or batch number, and the expiration date.)
[9] Accreditation Commission for Health Care (ACHC). “PCAB Accreditation for Modern Compounding Pharmacies.” https://achc.org/compounding-pharmacy/ (Accessed 2026-10-16. Supports: PCAB accreditation offered through ACHC; a receiving state’s board of pharmacy may require a specific license for pharmacies shipping compounded medications across state lines.)
[10] U.S. Food and Drug Administration. “Import Alert 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances.” Published 10/09/2026. https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html (Accessed 2026-10-16. Supports: detention of GLP-1 bulk drug substances at import, with a Green List of manufacturers excluded.)
[11] U.S. Food and Drug Administration. “MedWatch: The FDA Safety Information and Adverse Event Reporting Program.” Content current as of 10/15/2026. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program (Accessed 2026-10-16. Supports: consumers can report product quality problems and adverse events to FDA.)
[12] Federal Trade Commission. “Trade Regulation Rule on the Use of Consumer Reviews and Testimonials,” 16 CFR Part 465, 89 FR 68034 (published August 22, 2024; effective October 21, 2024). https://www.ecfr.gov/current/title-16/chapter-I/subchapter-D/part-465 (Accessed 2026-10-16. Supports: bans on fake or false consumer reviews (465.2), buying reviews conditioned on a particular sentiment (465.4), undisclosed insider reviews (465.5), and review suppression (465.7).)
[13] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: tirzepatide shortage resolution reissued December 19, 2024; semaglutide shortage resolved February 21, 2025; neither currently on the 503B bulks list or FDA’s drug shortage list.)
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication, and it does not vet, partner with, or endorse any compounding pharmacy or product. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Transformation Health does not accept payment from providers. How we make money.